Jingrui L. Liu
Jilin, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 46 publications
A randomized, double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics and ammonia-lowering effect of Rifaquizinone, an intestinally restricted investigational drug.
Journal: Expert opinion on investigational drugs
Published: January 22, 2026
Safety and pharmacokinetics of FCN-437c, a novel cyclin-dependent kinase 4/6 inhibitor, in Chinese patients with hepatic impairment.
Journal: Investigational new drugs
Published: April 28, 2025
The gene regulatory network reveals mechanisms of cadmium tolerance in Shanxin poplar.
Journal: Plant science : an international journal of experimental plant biology
Published: April 15, 2025
Safety, Pharmacokinetics and Antiviral Efficacy of Capsid Assembly Modulator Freethiadine in Healthy Volunteers and Chronic Hepatitis B Patients.
Journal: Liver international : official journal of the International Association for the Study of the Liver
Published: September 25, 2024
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of the Anti-IFNAR1 Monoclonal Antibody QX006N: A First-in-Human Single Ascending Dose Study in Healthy Chinese Volunteers.
Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Published: November 15, 2023
Safety, pharmacokinetics, and efficacy of rifasutenizol, a novel dual-targeted antibacterial agent in healthy participants and patients in China with Helicobacter pylori infection: four randomised clinical trials.
Journal: The Lancet. Infectious diseases
Published: October 18, 2023
Comparison of pharmacokinetics and safety between CE-fosphenytoin sodium, fosphenytoin sodium, and phenytoin sodium after intravenous and intramuscular administration in healthy volunteers.
Journal: Frontiers in pharmacology
Published: April 12, 2023
The effect of a single escalating dose of long-acting recombinant human follicle-stimulating hormone Fc fusion protein (KN015) on healthy, pituitary-suppressed women: first-in-human and randomized study on its pharmacokinetics, pharmacodynamics, and tolerability.
Journal: Expert opinion on investigational drugs
Published: December 20, 2022
Safety, pharmacokinetics and pharmacodynamics of a novel γ-aminobutyric acid (GABA) receptor potentiator, HSK3486, in Chinese patients with hepatic impairment.
Journal: Annals of medicine
Published: October 10, 2022
Pharmacokinetics, safety, and tolerability of TQC3564, a novel CRTh2 receptor antagonist: report of the first-in-human single- and multiple-dose escalation trials in healthy Chinese subjects.
Journal: Expert opinion on investigational drugs
Published: May 16, 2022
Last Updated: 09/26/2026